Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
Open accessThe DOI matches its Crossref record; 14 of the 15 references it cites were found in a registry or an index.
Abstract
Aims: In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether the benefits of empagliflozin varied by baseline health status and how empagliflozin impacted patient-reported outcomes in patients with heart failure with reduced ejection fraction. Methods and results: Health status was assessed by the Kansas City Cardiomyopathy Questionnaires-clinical summary score (KCCQ-CSS). The influence of baseline KCCQ-CSS (analyzed by tertiles) on the effect of empagliflozin on major outcomes was examined using Cox proportional hazards models. Responder analyses were performed to assess the odds of improvement and deterioration in KCCQ scores related to treatment with empagliflozin. Empagliflozin reduced the primary outcome of cardiovascular death or heart failure hospitalization regardless of baseline KCCQ-CSS tertiles [hazard ratio (HR) 0.83 (0.68–1.02), HR 0.74 (0.58–0.94), and HR 0.61 (0.46–0.82) for <62.5, 62.6–85.4, and ≥85.4 score tertiles, respectively; P-trend = 0.10]. Empagliflozin improved KCCQ-CSS, total symptom score, and overall summary score at 3, 8, and 12 months. More patients on empagliflozin had ≥5-point [odds ratio (OR) 1.20 (1.05–1.37)], 10-point [OR 1.26 (1.10–1.44)], and 15-point [OR 1.29 (1.12–1.48)] improvement and fewer had ≥5-point [OR 0.75 (0.64–0.87)] deterioration in KCCQ-CSS at 3 months. These benefits were sustained at 8 and 12 months and were similar for other KCCQ domains. Conclusion: Empagliflozin improved cardiovascular death or heart failure hospitalization risk across the range of baseline health status. Empagliflozin improved health status across various domains, and this benefit was sustained during long-term follow-up. Clinical trial registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03057977.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Treatment with empagliflozin did not affect visual analogue scale dyspnoea, diuretic response, NT-proBNP levels, or duration of hospital stay, but was safe, increased urinary output, and reduced a combined endpoint of worsening HF, re-hospitalization for HF, or death at 60 days compared with placebo.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [498]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206 · cited 6×
“However, in the current trial, neither NYHA class nor KCCQ health status at baseline exerted a statistically significant influence on the magnitude of the response to empagliflozin.(8,15) Importantly, even in patients with the worst KCCQ health status at baseline, the effect of empagliflozin to reduce the risk of hear…”
BackgroundMethodResultInfluentialSelf-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827 · cited 1×
“Quality of life outcome measures The KCCQ-23 is a 23-item, disease-specific measure that assesses the impact of heart failure on the perspective of patients of their health status.(10) The KCCQ-23 has been shown to be valid, reliable, and sensitive to clinical changes, and KCCQ scores are associated with death, hospit…”
BackgroundMonitoring clinical changes in patients with heart failure: A comparison of methods
Spertus, J., Peterson, E., Conard, M. W., Heidenreich, P. A., Krumholz, H. M., Jones, P., McCullough, P. A., Pina, I., Tooley, J., Weintraub, W. S., et al. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.12.010 · Cited by 562 · cited 1×
“We performed responder analyses to investigate the proportion of patients on empagliflozin and placebo who had >_5-, >_10-, and >_15point improvement or >_5-point deterioration in KCCQ scores at 3, 8, and 12 months; these thresholds are generally regarded as clinically meaningful changes.(13,14) Odds ratios (ORs) alon…”
MethodSelf-citationDevelopment and validation of a short version of the Kansas City Cardiomyopathy Questionnaire
Spertus, J. A., & Jones, P. G. (2015) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.001958 · Cited by 491 · cited 1×
“The KCCQ-23 has been shown to be valid, reliable, and sensitive to clinical changes, and KCCQ scores are associated with death, hospitalization, and costs.(11,12) The KCCQ-23 was completed via paper-and-pen version in person by patients at randomization, 3, 8, and 12 months (more specifically, at 12, 32, and 52 weeks)…”
MethodPacker, M., Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Pocock, S. J., Carson, P., Anand, I., Doehner, W., Haass, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051783 · Cited by 435
Self-citationNassif, M. E., Windsor, S. L., Tang, F., Khariton, Y., Husain, M., Inzucchi, S. E., McGuire, D. K., Pitt, B., Scirica, B. M., Austin, B., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042929 · Cited by 424
Kosiborod, M. N., Jhund, P. S., Docherty, K. F., Diez, M., Petrie, M. C., Verma, S., Nicolau, J. C., Merkely, B., Kitakaze, M., DeMets, D. L., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044138 · Cited by 350
Self-citationHealth-Related Quality of Life Outcomes in PARADIGM-HF
Lewis, E. F., Claggett, B. L., McMurray, J. J. V., Packer, M., Lefkowitz, M. P., Rouleau, J. L., Liu, J., Shi, V. C., Zile, M. R., Desai, A. S., et al. (2017) · Circulation: Heart Failure · doi:10.1161/circheartfailure.116.003430 · Cited by 219 · cited 1×
“5 points in favor of active treatment.(16,17) Nevertheless, if 5- and 10point thresholds are applied to the participants in the EMPERORReduced trial, patients in the empagliflozin groups were 15–20% more likely to show meaningful improvement and 15–20% less likely to show meaningful deterioration in health status.”
BackgroundSelf-citationEkman, I., Chassany, O., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Tavazzi, L., & Swedberg, K. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr343 · Cited by 206 · cited 1×
“5 points in favor of active treatment.(16,17) Nevertheless, if 5- and 10point thresholds are applied to the participants in the EMPERORReduced trial, patients in the empagliflozin groups were 15–20% more likely to show meaningful improvement and 15–20% less likely to show meaningful deterioration in health status.”
Background
Research works printed but not linked: 1
- Packer, 2019, Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial, Eur J Heart Fail, 21, 1270, 10.1002/ejhf.1536 · DOI
Cited by
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationAuthors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2333 · Cited by 2,171
Self-citation2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citationVirani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598
Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01429-5 · Cited by 996
Self-citation
Metadata
- Authors
- Butler, J., Anker, S. D., Filippatos, G., Khan, M. S., Ferreira, J. P., Pocock, S. J., Giannetti, N., Januzzi, J. L., Piña, I. L., Lam, C. S. P., Ponikowski, P., Sattar, N., Verma, S., Brueckmann, M., Jamal, W., Vedin, O., Peil, B., Zeller, C., Zannad, F., Packer, M., & the EMPEROR-Reduced Trial Committees and Investigators
- Affiliations
- University of Mississippi Medical Center (US)
- Berlin-Brandenburger Centrum für Regenerative Therapien (DE)
- National and Kapodistrian University of Athens (GR)
- French Clinical Research Infrastructure Network (FR)
- London School of Hygiene & Tropical Medicine (GB)
- McGill University Health Centre (CA)
- Harvard University (US)
- Wayne State University (US)
- National University of Singapore (SG)
- Wroclaw Medical University (PL)
- University of Glasgow (GB)
- St. Michael's Hospital (CA)
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim (Sweden) (SE)
- Baylor University Medical Center (US)
- Corresponding author
- Butler, Javed
- ORCID
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-01-09
- Volume
- 42
- Issue
- 13
- Pages
- 1203-1212
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC8014525
- OpenAlex
- W3118491390
- Cited by
- 183
- References
- 15
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 26 · 2023: 47 · 2022: 52 · 2021: 26
- FWCI
- 19.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Heart Journal (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- HAL (submittedVersion, cc-by-nc)
- Funders
- Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- empagliflozin, heart failure with reduced ejection fraction, health-related quality of life, Kansas City Cardiomyopathy Questionnaire, patient-reported outcomes, baseline health status, responder analysis, cardiovascular mortality, heart failure hospitalization, EMPEROR-Reduced trial, SGLT2 inhibitors, symptom scores, treatment response variability, long-term follow-up
- MeSH terms
- Benzhydryl Compounds, Glucosides, Heart Failure, Humans, Quality of Life, Stroke Volume
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. https://app.cochat.ai/papers/10.1093/eurheartj/ehaa1007
- The paper
- Butler, J., Anker, S. D., Filippatos, G., Khan, M. S., Ferreira, J. P., Pocock, S. J., Giannetti, N., Januzzi, J. L., Piña, I. L., Lam, C. S. P., Ponikowski, P., Sattar, N., Verma, S., Brueckmann, M., Jamal, W., Vedin, O., Peil, B., Zeller, C., Zannad, F., . . . the EMPEROR-Reduced Trial Committees and Investigators. (2021). Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal. https://doi.org/10.1093/eurheartj/ehaa1007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.